1. Home
  2. IMCR vs RBCAA Comparison

IMCR vs RBCAA Comparison

Compare IMCR & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • RBCAA
  • Stock Information
  • Founded
  • IMCR 2008
  • RBCAA 1974
  • Country
  • IMCR United Kingdom
  • RBCAA United States
  • Employees
  • IMCR N/A
  • RBCAA N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • RBCAA Major Banks
  • Sector
  • IMCR Health Care
  • RBCAA Finance
  • Exchange
  • IMCR Nasdaq
  • RBCAA Nasdaq
  • Market Cap
  • IMCR 1.4B
  • RBCAA 1.2B
  • IPO Year
  • IMCR 2021
  • RBCAA 1998
  • Fundamental
  • Price
  • IMCR $28.41
  • RBCAA $64.09
  • Analyst Decision
  • IMCR Buy
  • RBCAA
  • Analyst Count
  • IMCR 12
  • RBCAA 0
  • Target Price
  • IMCR $60.90
  • RBCAA N/A
  • AVG Volume (30 Days)
  • IMCR 403.7K
  • RBCAA 38.7K
  • Earning Date
  • IMCR 05-07-2025
  • RBCAA 04-28-2025
  • Dividend Yield
  • IMCR N/A
  • RBCAA 2.82%
  • EPS Growth
  • IMCR N/A
  • RBCAA 12.83
  • EPS
  • IMCR N/A
  • RBCAA 5.14
  • Revenue
  • IMCR $310,202,000.00
  • RBCAA $330,428,000.00
  • Revenue This Year
  • IMCR $20.52
  • RBCAA $1.56
  • Revenue Next Year
  • IMCR $8.57
  • RBCAA $3.87
  • P/E Ratio
  • IMCR N/A
  • RBCAA $12.44
  • Revenue Growth
  • IMCR 24.36
  • RBCAA 6.29
  • 52 Week Low
  • IMCR $23.15
  • RBCAA $46.83
  • 52 Week High
  • IMCR $62.74
  • RBCAA $80.68
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 51.56
  • RBCAA 52.98
  • Support Level
  • IMCR $26.37
  • RBCAA $59.08
  • Resistance Level
  • IMCR $27.67
  • RBCAA $63.70
  • Average True Range (ATR)
  • IMCR 1.76
  • RBCAA 2.96
  • MACD
  • IMCR 0.10
  • RBCAA 0.25
  • Stochastic Oscillator
  • IMCR 77.93
  • RBCAA 86.49

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.

Share on Social Networks: